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Abstract
Finnish hospital-integrated biobanks administer millions of formalin-fixed paraffin-embedded tissue samples collected within the
clinical diagnostics. According to the Finnish Biobank Act, these samples can be coupled with patients’ clinical follow-up data
and the data retrieved from national health registries. We collected a nationwide pulmonary carcinoid tumour series from Finnish
biobanks to study prognostic factors as well as to explore how the number of tumours found in the Finnish biobanks corresponds
to the number of tumours registered by the Finnish Cancer Registry (FCR). Finnish biobanks identified 88% of the tumours
registered by the FCR and were able to deliver 63%. The main reasons for lacking samples were paucity of resected primary
tumour tissue, incompatible primary diagnosis, and the absence of tissue blocks in the archives. The main bottleneck in the
sample application process was retrieving patient data. Altogether, we received 224 tumour samples with appropriate patient data
and identified six prognostic factors for shorter disease-specific survival: age over 56 years at the time of diagnosis, tumour size
over 2.5 cm, atypical histology, Ki-67 proliferation index higher than 2.5%, hilar/mediastinal lymph node involvement at the time
of diagnosis, and the presence of metastatic disease. In conclusion, the Finnish biobank infrastructure offers excellent opportu-
nities for tissue-based research. However, to be able to develop the biobank operations further, involving more medical knowl-
edge in the sample and data acquisition process is a necessity. Also, when working with tissue samples collected over decades,
histological expertise is essential for re-evaluation and re-classification of the samples.
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Introduction
Human biological samples with associated clinical data are a
fundamental resource for advancing medical research. At the
European level, hundreds of biobanks aim to assist researchers
by providing biological materials [1]. At their best, biobanks
can be valuable tools for preclinical, clinical, and translational
studies aiming to advance our understanding of human health
and disease. Within Europe, the BBMRI-ERIC research infra-
structure consortium coordinates biobanking-related activities
across countries. However, the legislation, organization of
biobanks, and their capabilities across countries vary
considerably.
Finland enacted specific legislation for biobanking in
September 2013 providing the legal framework for the collec-
tion, storage, and usage of samples and related clinical data for
biomedical research [2]. Between 2014 and 2018, 10 biobanks
were established and started sample collection. Six of the
biobanks are university or central hospital integrated
collecting mainly blood and tissue samples from their patients.
The rest are national biobanks who collect and administer
samples, e.g. from healthy blood donors or for the needs of
population-based health studies. Since every Finn has a
unique personal identity number, combining biological sam-
ples with data from multiple national or local health registers
is straightforward.
Informed consent is the primary justification for processing
the samples and data. However, this consent can be broad and
cover several unspecified future research purposes in which
samples and data can be utilized. In addition, the Finnish
Biobank Act also affords a pathway for transferring the clin-
ical samples, stored within the healthcare system at the time
the law entered into force, to biobanks without consent. In this
setting, the approval is given by a regional ethics committee,
and the individuals concerned are notified and given the pos-
sibility to opt out. Major Finnish clinical pathology laborato-
ries have utilized this opportunity and transferred their sample
archives into local hospital-integrated biobanks.
A cancer is typically defined as ‘common’ or ‘rare’ based
on its incidence. While no universally recognized cutoff ex-
ists, the RARECARE–Surveillance of Rare Cancers in
Europe working group defines a rare cancer to occur at a
frequency of 6 cases per 100 000 individuals per year [3]. At
the European level, 24% of all new cancer diagnoses each
year are considered rare [4].
One of the rare cancer forms is pulmonary carcinoid (PC)
tumour, a subgroup of pulmonary neuroendocrine tumours
(NETs) together with large-cell neuroendocrine carcinoma
and small-cell lung cancer [5]. Globally, the incidence of PC
tumours varies between 0.5 and 1.5 per 100 000 persons per
year [3, 6–8]. PC tumours are further classified by histology
into typical carcinoid (TC) and atypical carcinoid (AC) tu-
mours [5]. The primary treatment for PC tumours is surgery
[9]. In general, their prognosis is favourable, especially when
resected, with a 5-year survival rate of more than 90%, but 10–
20% of the tumours metastasize resulting in a lower survival
rate [10–13].
Rare cancers are often difficult to study due to a lack of
study material. While hundreds of patients may be living
with a given rare cancer, the geographic dispersion of the
patients limits the number of cases seen at a single insti-
tution. Thus, the aim of this study was to collect a nation-
wide PC tumour cohort through the Finnish biobank in-
frastructure to study clinical and histological prognostic
factors of PC tumours. Moreover, we aimed to explore
how the number of tumours found in the Finnish biobanks
corresponds to the number of tumours registered by the
Finnish Cancer Registry (FCR). We were also interested
to compare the biobank database diagnosis, obtained from
primary pathology reports, with the diagnosis after re-
evaluation of the tumour by an experienced pathologist.
Furthermore, we aimed to study the application process-
ing times in biobanks and to identify possible bottlenecks
in the sample and data delivery process.
Materials and methods
Pulmonary carcinoid incidence data
The FCR operates under the National Institute for Health and
Welfare to collect population-based data on the cancer inci-
dence in Finland. Nationwide registration of cancer cases
started in 1953 and became compulsory for institutions and
health care professionals in 1961 [14]. Disease information is
received from public and private hospitals, laboratory reports,
and death certificates [15]. The degree of data completeness in
cancers affecting the respiratory tract is estimated to be 97.2%
[14]. We requested information from the FCR on lung cancer
and PC tumour incidence from 1990 to 2013. Age-
standardized incidence (per 100 000 person-years) rates were
calculated using the world standard population (1966) for
weights.
Collecting a nationwide pulmonary carcinoid patient
series
Currently, six Finnish hospital-integrated biobanks administer
tumour samples of PC patients. These biobanks form a nation-
al network covering the whole country (Fig. 1).We applied for
primary PC tumour samples resected between 1990 and 2013,
coupled with patients’ clinical and outcome data. Biobanks
obtained clinical data from hospital registries, survival data
from the Population Register Centre, and cause of death data
from Statistics Finland.
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The Finnish Biobank Act provides a lawful basis for
the use of biobanked samples and data for scientific re-
search without project-specific consent from the patients
involved. However, each biobank has their own Scientific
and Ethical Committee that evaluates the applications and
states whether the researchers should be granted access to
samples and data. The Scientific and Ethical Committees
of all involved hospital-integrated biobanks approved this
study.
Histological re-evaluation of tumour specimens
All histological specimens were re-evaluated from original
microscopy slides by a pathologist with special expertise in
pulmonary pathology. Tumours were classified according to
the World Health Organization 2015 classification criteria, in
which TC is defined as presenting < 2 mitoses per 2 mm2 and
a lack of necrosis whereas AC presents as 2–10 mitoses per
2 mm2 a nd / o r f o c i o f n e c r o s i s ( F i g . 1 ) [ 5 ] .
a b
Fig. 1 Finnish biobank network and histological images of typical
carcinoid (TC) and atypical carcinoid (AC) tumour. a All Finnish
hospital-integrated biobanks administering pulmonary carcinoid (PC) tu-
mour samples with the population base given in parentheses (as of 31
December 2017). b Representative histological images of TC tumour
(above) and AC tumour (below, arrow for mitosis). Scale bar 50 μm,
original magnification × 40. Images were obtained from digitized slides
with the CaseViewer software
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Immunohistochemical labelling against chromogranin A,
synaptophysin, and pan keratin were used to confirm the neu-
roendocrine differentiation.
Next-generation tissue microarray
The next-generation tissue microarray (TMA) technique relies
on careful planning and design, digital pathology, and auto-
mated tissue arraying [16]. TMA blocks were created in col-
laboration with the biobanks. Briefly, after identifying the
most suitable formalin-fixed paraffin-embedded (FFPE) tissue
blocks per case, fresh slides were sectioned, stained with
haematoxylin and eosin, and digitized. Annotations for the
TMAs were marked on the digitized slides in accordance with
the following principles: two cores from the middle of the
tumour, two cores from the tumour border, two cores from
the non-tumour area, and one core from the bronchus, if ap-
plicable. The TMAs were constructed with TMA Grand
Master (3DHISTECH, Budapest, Hungary) or Galileo TMA
CK4500 microarrayer (Isenet, Milan, Italy) using 1 mm
punches.
Immunohistochemistry and evaluation of stainings
TMA sect ions obtained from the biobanks were
immunolabelled for chromogranin A, synaptophysin, pan ker-
atin, and Ki-67 in the clinical pathology laboratory at the
Helsinki University Hospital as previously described [17].
Briefly, the sections were deparaffinized and antigen retrieval
was performed using CC1 reagent (VentanaMedical Systems,
Inc., Tucson, AZ, USA) and/or Protease 3 (Ventana Medical
Systems). The primary antibodies (chromogranin A (clone
DAK-A3, dilution 1:800, Dako, Agilent Pathology
Solutions, Santa Clara, CA), synaptophysin (clone SP11,
ready-to-use, Ventana Medical Systems), pan keratin (clone
AE1/AE3 & PCK26, ready-to-use, Ventana Medical
Systems), and Ki-67 (MIB-1, dilution 1:100, Dako) were in-
cubated, and the immunoreactions were detected using either
an ultraView or OptiView Universal DAB Detection Kit
(Ventana Medical Systems). All slides were counterstained
with haematoxylin.
Stained slides were digitized with a Pannoramic scanner
(3DHISTECH) and expression patterns for chromogranin A,
synaptophysin, and pan keratin were evaluated from the dig-
itized slides as previously described [17]. The proliferation
index was evaluated according to the Ki-67 immunoreactivity
in the nuclei of the highest labelling region with the
ImmunoRatio image analysis software [18].
Statistical analyses
The Kaplan–Meier method and the log-rank test were applied
to estimate cumulative survival probabilities and to
graphically display the disease-specific survival (DSS) curves.
The log-log 95% confidence intervals (CIs) were calculated
for the survival rates. The significance of hazard ratios for
clinicopathological variables was tested with univariate Cox
regression. Receiver operating characteristics curves were
used to estimate a cutoff value for Ki-67 as a prognostic indi-
cator. An arbitrary size of 2.5 cm was used as a tumour size
cutoff for survival. Survival was calculated from the date of
surgery to the last date of follow-up or death, and non-disease-
specific deaths were censored to obtain DSS. A significant
difference was predetermined to be a P value less than 0.05;
two-sided tests were used. Analyses were performed using
IBM SPSS Statistics 24 (IBM, Armonk, NY, USA) and SAS
for Windows 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Lung cancer and pulmonary carcinoid tumour
incidence according to the Finnish Cancer Registry
Between 1990 and 2013, altogether 54 166 lung cancers were
registered by the FCR. Of these, 523 (1.0%) were classified as
PC tumour. In 1990, the age-standardized lung cancer inci-
dence was 26 per 100 000 persons, and the PC tumour inci-
dence 0.2 per 100 000 persons. By 2013, the lung cancer
incidence decreased to 21 per 100 000 persons while the PC
tumour incidence increased to 0.34 per 100 000.
Application processing times in different biobanks
We submitted first two applications for biobanked samples
and associated data in October and November 2016. The re-
sponse times from the approval of the biobanks’ Scientific and
Ethical Committees to receiving the samples and data were 11
and 12 months, respectively. At that time, one of the biobanks
was not able to deliver electronic medical record information
and we had to apply for it from the local university hospital.
The next three applications were submitted in February,
May, and July 2017. For these applications, the response times
were 15, 17, and 22 months. The sixth application was ap-
proved in September 2018 with a response time of 6 months
for receiving the samples and data.
Re-evaluation of the tumours
We obtained altogether 242 tumours, resected between 1990
and 2013, from the biobanks. Of these, seven were excluded
due to lack of either chromogranin A or synaptophysin ex-
pression, and/or because of a very high Ki-67 proliferation
index (> 45%) together with incompatible PC morphology.
Three more tumours were excluded because they were metas-
tases from gastroenteropancreatic NETs, not primary
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pulmonary NETs, and four since only biopsy material was
available. In addition, one patient was excluded since he had
multiple small tumours and only one was enucleated. Three
patients were excluded because of insufficient follow-up data.
The final cohort included 224 tumours. Based on histolog-
ical re-evaluation according to current diagnostic criteria [5],
21% of the original classifications at the biobank database
were changed: 31 TCs were re-classified as ACs and 16
ACs were re-classified as TCs. One tumour diagnosed primar-
ily as neuroendocrine carcinoma was re-classified as TC. In
summary, after re-evaluation, 182 (81%) tumours were classi-
fied as TCs and 42 (19%) as ACs.
Comparison between the number of pulmonary
carcinoid tumours in the Finnish Cancer Registry
and the number of pulmonary carcinoid tumours
found in the biobanks
As one of the biobanks was able to provide only tumour sam-
ples collected after year 2000, we included in the biobank
performance analysis a 10-year period from 2002 until 2011
(Table 1). During this time period, 256 PC tumours were reg-
istered by the FCR corresponding to 1.1% of all registered
lung cancers (n = 23 328). Of these, 233 (91%) were histolog-
ically confirmed indicating that these cases might be included
in the biobank collections. However, single patients may have
been operated on in regional hospitals whose sample archives
had not yet been transferred to any biobank.
Biobanks identified 206 PC tumour tissue samples from
their sample registries corresponding to 88% of all histologi-
cally confirmed PC tumours registered by the FCR. Of the 206
tumours, biobanks were able to deliver tissue material from
129 (63%) tumours. Of these, we had to exclude 12 tumours
(9%) due to reasons stated above. Finally, 117 tumours were
included in our patient series corresponding to 57% of all PC
tumours identified by the biobanks between 2002 and 2011.
Demographics and clinical findings of the pulmonary
carcinoid patients
Demographic, surgical, histopathological, and clinical charac-
teristics of the patients are described in Table 2. We included
here all 224 patients operated on between 1990 and 2013.
Of 224 patients, 161 (72%) underwent lymph node dissec-
tion at primary surgery. Two (1%) patients had metastatic
lesions in bones, liver, and pleura at the time of primary sur-
gery. In addition, during the follow-up, 20 (9%) patients de-
veloped a recurrent disease and/or distant metastases in bones,
liver, adrenal gland, brain, ovary, or pancreas. The average
time from primary surgery to the recurrent or metastatic dis-
ease was 58 months (range 3–224 months).
Survival analysis
The median follow-up time of the patients was 11.4 years
(mean 12.7; range 0–28.0 years). Of 224 patients, 47 died
during the follow-up. Fourteen patients died with evidence
of recurrent or metastatic carcinoid tumour (6 TC patients
and 8 AC patients), 2 patients died because of complications
after surgery, and 31 patients died from unrelated causes. The
average survival time for the patients with disease-specific
death was 6.8 years (range 1.1–17.4 years).
The disease-specific 5- and 10-year survival rates among
all PC patients were 97% (95% CI, 94–99%) and 95% (95%
CI, 91–97%), respectively. Among the TC patients, 5- and 10-
year DSS rates were 99% (95% CI, 96–100%) and 98% (95%
Table 1 Number of pulmonary carcinoid tumours according to the Finnish Cancer Registry (FCR) and the number of tumours found and delivered by
the biobanks between 2002 and 2011
University hospital
district
Local biobank(s) FCR
all
FCR histologically
confirmed
Tumours found in the
biobanks
(n) (n) origa.
(n)
deliv.b
(n)
conf.c
(n)
Helsinki Helsinki Biobank 93 85 72 68 66
Turku Auria Biobank 46 42 42 18 18
Tampere Finnish Clinical Biobank Tampere 60 54 26 9 7
Kuopio Biobank of Eastern Finland and Central Finland
Biobank
34 30 34 18 14
Oulu Northern Finland Biobank Borealis 23 22 32 16 13
All 256 233 206 129 117
aNumber of tumours the biobank was able to identify from its sample registry
b Number of tumours the biobank was able to deliver
c Number of tumours we confirmed to be primary resected PC tumours based on the morphology, immunohistochemistry, and patient data
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Table 2 Demographic, histopathological, and treatment characteristics of the patients
Variable TC AC All
Sex
Male 66 (36%) 21 (50%) 87 (39%)
Female 116 (64%) 21 (50%) 137 (61%)
Age
Mean 54 54 54
Median 55 56 55
Range 19–86 23–77 19–86
Location of the tumour
Right lung 111 (61%) 24 (57%) 135 (60%)
Upper lobe 25 9
Middle lobe 35 8
Lower lobe 40 7
Main bronchus 2 0
Two lobes 8 0
Unknown 1 0
Left lung 69 (38%) 18 (43%) 87 (39%)
Upper lobe 34 7
Lower lobe 34 6
Main bronchus 1 3
Unknown 0 2
Unknown 2 (1%) 0 2 (1%)
Surgical procedure
Lobectomy 90 (58%) 24 (60%) 114 (58%)
Sleeve resection 17 (11%) 8 (20%) 25 (13%)
Segmentectomy 17 (11%) 1 (3%) 18 (9%)
Bilobectomy 13 (8%) 2 (5%) 15 (8%)
Wedge resection 12 (8%) 1 (3%) 13 (7%)
Pneumonectomy 3 (2%) 4 (10%) 7 (4%)
Enucleation 3 (2%) 0 3 (2%)
Unknown 27 2 29
Tumour size (cm)
≤ 1 46 (25%) 11 (26%) 57 (25%)
1.1–2.5 91 (50%) 19 (45%) 110 (49%)
> 2.5 42 (23%) 11 (26%) 53 (24%)
Unknown 3 (2%) 1 (2%) 4 (2%)
Ki-67 proliferation index
< 1% 57 (32%) 11 (26%) 68 (31%)
1–2.5% 102 (58%) 21 (50%) 123 (56%)
> 2.5% 18 (10%) 10 (24%) 28 (13%)
Unknown 5 0 5
Hilar/mediastinal (N1/N2) nodal involvement at diagnosis
Yes 9 (7%) 8 (21%) 17 (11%)
No 114 (93%) 30 (79%) 144 (89%)
Not examined 59 4 63
Neoadjuvant treatment
Chemotherapy 0 1 1
Radiotherapy 0 1 1
Both 0 1 1
Distant metastasis
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CI, 94–99%), respectively. Among the AC patients, the 5-year
DSS rate was 90% (95% CI, 76–96%), and the 10-year DSS
rate 81% (95% CI, 63–90%).
We evaluated the association between clinical and patho-
logical variables and patient outcomes with the Kaplan–Meier
method and the log-rank test. We found that age over 56 years
at the time of diagnosis, tumour size over 2.5 cm, atypical
histology, Ki-67 proliferation index higher than 2.5%, hilar/
mediastinal lymph node involvement at the time of diagnosis,
and the presence of metastatic disease were associated with a
shorter DSS (Fig. 2). In univariate Cox survival regression
analysis, all abovementioned factors were associated with a
risk of worse outcome (Table 3). Because of a low number of
disease-specific deaths (n = 14), we could not perform a reli-
able multivariate analysis.
Discussion
In the present study, we collected one of the largest PC tumour
patient series reported, utilizing the Finnish biobank infra-
structure. In this series of 224 tumours, we identified six fac-
tors that seem to predict PC patient outcome: age over 56 years
at the time of diagnosis, tumour size over 2.5 cm, atypical
histology, Ki-67 proliferation index higher than 2.5%, hilar/
mediastinal lymph node involvement at the time of diagnosis,
and the presence of metastatic disease. We also showed that a
nationwide hospital-integrated biobank network makes it pos-
sible to collect reasonably large cohorts of rare diseases.
Between 2002 and 2011, 251 PC tumours were registered
by the FCR, corresponding to 1.1% of all lung cancers in
Finland. This percentage is equal to reports from other
Nordic countries [19, 20]. However, the proportion of AC
tumours (n = 10, 4%) was low. This is mainly explained by
the nomenclature applied by the FCR: ICD-O-3 was intro-
duced in 2007, and ACs have been registered as ACs only
after that. Before 2007, ACs were registered as neuroendo-
crine NOS. Additionally, we observed an increase in PC tu-
mour incidence from 1990 to 2013. The same has been no-
ticed in previous reports [6, 21, 22]. Possible explanations
include improved imaging methods and diagnostic protocols
together with better awareness among clinicians.
The six Finnish biobanks included more than 88% of the
cases registered by the FCR. The rest of the samples are prob-
ably stored in smaller pathology departments that have not yet
transferred their sample repositories to any biobank. However,
biobanks were able to deliver only 63% of their found samples
to us. One main reason was paucity or lack of tissue material.
According to the Finnish Biobank Act, a sample collected
primarily for diagnostic purposes can be used for research
purposes only if possible future patient care is not jeopardized.
This dualistic nature of biobanked samples prevents deliver-
ing scarce samples for research. In addition, the preliminary
search for tumour numbers is based on the registry informa-
tion the biobank received from the pathology laboratory at the
time the samples were transferred into the biobank. In some
cases, the primary diagnosis in the database was incorrect and
the biobank pathologist scanning the cases excluded these
tumours (e.g. paragangliomas). Also, a minority of the sam-
ples found were biopsies unsuitable for our study. Moreover,
several samples were not found in the biobank archives. A
plausible explanation for this is the practice before the
biobanking legislation: the use of samples for research pur-
poses was not registered and followed-up diligently, and some
samples could thus not be located anymore.
Based on our experience, the sample application process
was slow in all biobanks. One obvious reason was that for
most of the biobanks, our application was among the first
ones, and the sample and data delivery processes were still
being built. This concerns especially the collection of clinical
follow-up data from the patient records. Biobanks also faced
challenges in finding patient data for older cases since, based
Table 2 (continued)
Variable TC AC All
At diagnosis 0 2 2
During follow-up 11 9 20
Treatment of metastatic disease
Metastases surgery only 4 0 4
Chemo/radiotherapy only 1 3 4
SSA only 2 1 3
SSA+ chemo/radiotherapy 1 4 5
SSA+ PRRT 1 1 2
SSA+ PRRT+
chemo/radiotherapy
1 1 2
No treatment, only follow-up 1 1 2
AC atypical carcinoid, PRRT peptide receptor radionuclide therapy, SSA somatostatin analogue, TC typical carcinoid
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on the Decree of the Ministry of Social Affairs and Health on
Patient Records (298/2009), Finnish hospitals are regulated to
conserve the patient data for only 12 years after the patient’s
death. Also, even though patient data has been collected in
electronic form for almost two decades, it is mainly not in a
structured form but as freely written text. Free text, together
with several different software programs applied nationwide
for storing it, places a major challenge for mining patient data.
Understandably, in addition to technical skills, medical
knowledge is needed for accurate patient data mining. We
noticed clear regional differences in the capability of the
biobanks in collecting and processing the patient data.
One special feature of the Finnish biobanking is the possi-
bility to combine patient data with national registry data. Since
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Fig. 2 Disease-specific survival probabilities based on age at the time of
surgery (a), histological subtype (b), Ki-67 proliferation index (c), tumour
size (d), presence of lymph node involvement at the time of primary
surgery (e), and presence of metastatic disease during follow-up (f). P
values were calculated with the log-rank test. AC, atypical carcinoid; LN,
lymph node; TC, typical carcinoid
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1964, all Finnish citizens have had a unique personal identi-
fication number that follows the person from birth to death
[23]. In addition, record keeping in general for administrative
and statistical purposes has a long tradition in Finland. Due to
these two issues, combining patient data from local hospital
records with national records is straightforward. For this study,
the biobanks obtained the patient survival data from the
Population Register Centre and the cause of death data from
Statistics Finland.
All Finnish biobanks have excellent facilities and technical
skills for processing FFPE tissue into TMA format. The sam-
ples were digitized, which allows the researchers to choose the
morphologically most suitable samples for their study as well as
to annotate representative areas for TMAs by themselves, de-
spite the geographic location. In general, two copies of the
TMA blocks are prepared and the biobanks deliver researchers
unstained sections, not the TMA blocks. This allows the TMA
material to be used in other studies in the future as well.
In addition to general slowness of the biobanks’ processes,
a major bottleneck in the sample request process was submit-
ting separate applications to each biobank, with varying forms
and content. However, since the beginning of our study in
2016, the situation has improved. Today, all hospital-
integrated biobanks can be approached with one application
through the Fingenious gateway (www.fingenious.fi, The
Finnish Biobank Cooperative).
Regardless of the challenges, we succeeded in collecting a
nationwide PC tumour patient series coupled with clinical
follow-up and outcome data. Histological re-evaluation of
the tumours resulted in changed classification in 21% of the
tumours. Based on the TMA sections and clinical information
received from the biobanks, we performed survival analysis.
The 5- and 10-year DSS rates were higher than in most pre-
vious studies [13, 24, 25]. The main reason for this might be
that we calculated the DSS while others reported the overall
survival.
As expected and shown earlier, atypical histology, hilar/
mediastinal lymph node involvement at the time of diagnosis,
and the presence of metastatic disease are associated with a
worse outcome [10, 12, 13, 17, 26]. Previous reports have also
pointed out the importance of the Ki-67 proliferation index as
a prognostic factor [27–30]. Tumour size as well as age at the
time of diagnosis are identified as prognostic factors with
different cutoff values [17, 26, 31, 32].
The data on PC tumours presented here together with the
stained TMA sections are now available to other researchers
on application. The Finnish Biobank Act enables the use of
samples and data for both academic and industrial research
purposes, both in Finland and abroad. In addition, the study
results should enrich the biobank through the return of raw
data from the researchers’ experiments to the biobank.
In conclusion, the Finnish biobank infrastructure offers ex-
cellent opportunities for medical tissue-based research.
Biobanks were able to find 88% of the patient cases registered
in the nationwide FCR and process 63% of them into TMA
format. The main bottleneck in the process was collecting
clinical follow-up data because of insufficient medical and
technical expertise in the biobanks. To be able to develop
the biobank process further, involving more medical knowl-
edge in the sample and data acquisition is a necessity. Also,
when working with tissue samples collected over decades,
pathology expertise is needed for histological re-evaluation
of the samples.
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Table 3 Analysis of potential risk factors for disease-specific mortality using univariate Cox regression
Risk factor p value HR (95% CI)
Age (> 56 vs. ≤ 55) 0.023 4.5 (1.2–16.7)
Gender (female vs. male) 0.281 0.5 (0.2–1.6)
Tumour size (≥ 2.5 cm vs < 2.5 cm) 0.045 3.2 (1.0–9.9)
Histological type (AC vs. TC) < 0.001 7.8 (2.5–23.8)
Ki-67 proliferation index (≥ 2.5 vs < 2.5) < 0.001 11.518 (3.7–35.8)
Hilar/mediastinal lymph node involvement at the time of primary surgery (yes vs. no) < 0.001 11.9 (3.6–39.2)
Presence of metastatic disease (yes vs. no) < 0.001 34.7 (10.1–119.8)
AC atypical carcinoid, CI confidence interval, HR hazard ratio, TC typical carcinoid
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